MediGene sells European rights to Oracea
MediGene has sold the European rights to Oracea for rosacea to Galderma Laboratories for €8 million upfront and up to €32 million in total based on certain commercialization milestones. Release
THE LIBRARY: WEBINAR
Getting the most PoC data in Phase I cancer studies
The hunt for proof-of-concept data is steadily moving upstream in the clinic. Join FierceBiotech on June 12th as three clinical trial experts tackle the question of how you can best design a Phase I study to get a readout on efficacy. Topics will include: enrollment, dosing and the best possible use of biomarkers for experimental cancer drugs. Register Today!
Latest Commentary
EVENTS
- MDMA Annual Meeting May 30th - June 1st, 2012 — Washington, DC
- Clinical Trials Eastern Europe Webinar SeriesMay 15-June 12 — Eastern Europe
- What's your BIO?June 18-21, 2012 — Boston, MA
Press Releases
- Chronic Pain Is Relieved by Cell Transplantation in Lab Study
- Drug-vaccine combo better for breast cancer
- Marked for destruction: Newly developed compound triggers cancer cell death
- Orthofix International Completes Divestiture of Sports Medicine Business Unit
- ConforMIS iTotal CR Knee Replacement System Wins Silver in 2012 Medical Design Excellence Awards
- More Press Releases
Featured Jobs
-
Supervisor, QC Chemistry - 3rd Shift Job
Celgene Corporation - Phoenix, AZ, US -
Sr. Director/Executive Director of Operations, Inflammation and Immunology CRD Job
Celgene Corporation - Tokyo, Ja, US -
Director, Pharmacovigilance and Drug Safety
TESARO - Waltham, MA -
Neurosciences Knowledge Group Lead
Merck - Rahway, NJ - Kenilworth, NJ - West Point, PA - Boston, MA -
Research & Development Chemist
C3 Jian - Marina Del Rey, CA
Comments